Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06378047 | Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer | PHASE1 | COMPLETED | 2 | — | — | Apr 10, 2024 | Sep 15, 2025 | Feb 9, 2026 | 1 | United States |
The number of participants who experience a high-grade (grade 3-5) adverse events based on NCI common terminology criteria for adverse events (CTCAE) version 5 related to treatment.
| Arm | Type | Description |
|---|---|---|
| IRE/Pembrolizumab | EXPERIMENTAL | Participants will undergo irreversible electroporation (IRE) using the NanoKnife system. About 1 week following IRE, study participants will receive a 200mg dose of pembrolizumab. |
| Name | Type | Description |
|---|---|---|
| Pembrolizumab | DRUG | Pembrolizumab is an immunotherapy that will be administered via IV infusion. |
| Irreversible Electroporation | DEVICE | Participants will undergo IRE as standard of care treatment. |
Inclusion Criteria: * Participant must consent to enrollment in the Moffitt Cancer Center (MCC) Total Cancer Care (TCC) Protocol for tissue and blood banking and must have their initial biopsy tissue available. * Participant must be willing and able to comply with scheduled visits, treatment plans,...